What this page tracks first
The first layer is current product information: the current Wegovy label, the current Ozempic label, and the main warnings or precautions that affect GI injuries, pregnancy, retinopathy, thyroid warnings, pancreatitis, gallbladder disease, and delayed gastric emptying.
After labeling, the next layer is public litigation structure, regulator actions, and trials or peer-reviewed studies that materially change how a topic should be described.
Which topics are drawing the most attention
Severe GI injury remains the biggest public topic by volume. Gastroparesis, persistent vomiting, dehydration, bowel-obstruction questions, pancreatitis, and gallbladder disease all sit in or around that cluster, but each one needs cleaner medical distinctions than most generic lawsuit pages provide.
The vision side is the other major current topic. NAION is now significant enough that it deserves its own page because current ophthalmology research, EMA's 2025 decision, and the separate NAION MDL all changed the public landscape.
The current court and regulator picture
As of April 1, 2026, the federal GLP-1 MDL picture includes the larger GI-injury MDL and the newer NAION vision-loss MDL.
FDA removed suicidality warning language from the obesity GLP-1 labels in January 2026, and FDA separately announced action against non-FDA-approved GLP-1 products in February 2026. Both developments changed the public safety picture.
Trials and studies worth watching
ClinicalTrials.gov entries are useful because they show where the medical conversation may move next. The most relevant current entries here are the studies on gastric contents, semaglutide-induced gastric retention, and reproductive or IVF questions.
Peer-reviewed ophthalmology work matters too. The NAION literature shows how quickly a once narrow question can become part of the regulator and litigation picture.
Why approved and non-approved products need to stay separate
Current FDA communications make clear that non-FDA-approved GLP-1 products and misleading compounded-product marketing create a different problem from the approved semaglutide-label discussion. That distinction matters because public reports about compounded products, salts, counterfeits, or dosing errors should not be automatically folded into claims about the approved brand-name drugs.
Pages about approved semaglutide products should stay anchored to the approved labels, while any page about compounded or non-approved products should be explicit about that difference.